Immunocore Aims For $100m IPO After Immunotherapy Success
Proof-Of-Concept For TCR platform
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.
You may also be interested in...
EU reviewers will decide this week whether to grant accelerated assessment to a handful of new dug candidates that will soon be filed for approval.
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
Another promising British-based company, GW Pharma, has been acquired, this time by mid-sized US player Jazz. Is it a pipedream that a UK biotech could be in a position to pull off a $7bn takeover of its own or does it really not matter?